Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Howard, P. Bach, E. Berndt, R. Conti (2014)
Pricing in the Market for Anticancer DrugsNBER Working Paper Series
P. Bach (2015)
New Math on Drug Cost-Effectiveness.The New England journal of medicine, 373 19
P. Weiden, N. Flournoy, E. Thomas, R. Prentice, A. Fefer, C. Buckner, R. Storb (1979)
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.The New England journal of medicine, 300 19
Tisagenlecleucel (CTL019) for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
P. Bach (2014)
Indication-specific pricing for cancer drugs.JAMA, 312 16
P. Bach, S. Pearson (2015)
Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.JAMA, 314 23
(2017)
Outcomes-based drug contracts do not move us closer to value
(2017)
Profit on $475,000 Novartis cancer drug could be a while coming
This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.
JAMA – American Medical Association
Published: Nov 21, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.